01. Doctor Overview

Doctor Overview

Dr. Konstantin H. Dragnev is Medical Oncologist/Hematologist at the Norris Cotton Cancer Center (NCCC) in New Hampshire. He focuses on lung cancer prevention, targeted molecular therapies, lung cancer, mesothelioma and esophageal cancer. He serves on the NCCC Clinical Cancer Review Committee and as the Co-Chair of the Alliance Publications Committee.

Dr. Dragnev’s research focuses on a number of promising tactics for improving difficult cancer treatments. He has studied the role of cytochrome P-450 in chemically associated cancer development as well as a potential cyclin D1 pathway for lung cancer therapy. Dr. Dragnev is the principal investigator on six different studies and participates as a co-investigator in at least two more.

02. Fast Facts

Doctor Fast Facts

Main Specialty: Hematology, Oncology

Other Interests & Specialties: Lung, esophageal and thoracic cancers, molecularly targeted therapies, lung cancer prevention, clinical trials in non-small cell and small cell lung cancer, mesothelioma and esophageal cancer.

Certifications, Awards & Accolades: Board Certifications in Medical Oncology, Hematology and Medical Oncology, Castle Connolly Regional Top Doctors Award

Education & Experience:

  • Fellowship in Oncology from Bulgarian Medical Academy
  • Research Fellowship from the National Cancer Institute, National Institutes of Health
  • Fellowship in Hematology and Oncology from Memorial Sloan-Kettering Cancer Center
  • Fellowship in Hematology/Oncology from Dartmouth-Hitchcock Medical Center
  • Residency in Internal Medicine from District Hospital
  • Residency in Internal Medicine from Baylor College of Medicine Associated Hospitals
  • Medical Degree from Higher Institute of Medicine
03. Publications


A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancerJournal of Thoracic Disease. September 2018;10(9):5531-5537. doi: 10.21037/jtd.2018.09.10

The role of a palliative care intervention in moderating the relationship between depression and survival among individuals with advanced cancerHealth Psychology. December 2017;36(12):1140-1146. doi: 10.1037/hea0000544